Ramm Pharma (TSE:RAMM)
:RAMM
Top Page
Ramm Pharma
(RAMM)
Select Model
Select Model
Rating:46Neutral
Price Target:
C$0.02
▼(-66.67% Downside)
Action:ReiteratedDate:03/09/26
The score is held down primarily by weak financial performance (volatile margins, ongoing losses, and continued negative operating/free cash flow), with technicals also bearish (price below key moving averages and negative MACD). Low leverage and improved 2025 loss/cash-burn trends provide some support, but valuation is limited by negative earnings and the absence of a dividend signal.
Positive Factors
Low Leverage
Very low debt (debt-to-equity ~1–2%) materially reduces refinancing and interest-rate pressure, preserving financial optionality. For a cash-consuming biotech, low leverage lengthens runway, lowers insolvency risk, and gives management time to execute restructuring or commercialization initiatives without urgent debt maturities.
Negative Factors
Declining Revenue
An ongoing revenue decline erodes scale and makes fixed-cost absorption harder, limiting margin recovery and cash generation. For a specialty/generic drug maker, falling sales indicate product, market-share, or demand issues that are structural unless new launches or contracts reverse the trend.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Very low debt (debt-to-equity ~1–2%) materially reduces refinancing and interest-rate pressure, preserving financial optionality. For a cash-consuming biotech, low leverage lengthens runway, lowers insolvency risk, and gives management time to execute restructuring or commercialization initiatives without urgent debt maturities.
Read all positive factors
Ramm Pharma (RAMM) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$1.79M
Dividend YieldN/A
Average Volume (3M)118.29K
Price to Earnings (P/E)―
Beta (1Y)-2.39
Revenue Growth-15.51%
EPS Growth-49.26%
CountryCA
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding119,389,320
10 Day Avg. Volume262,784
30 Day Avg. Volume118,288
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.31
Price to Sales (P/S)0.53
P/FCF Ratio-1.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Ramm Pharma Business Overview & Revenue Model
Company Description
RAMM Pharma Corp. engages in the research and development, production, and sale of cannabinoid pharmaceutical formulations, pharmaceuticals, cosmetics, nutraceutical products, and resale of medical supplies products in Canada and internationally. ...
How the Company Makes Money
Ramm Pharma generates revenue primarily through the sales of its proprietary drug products and formulations. The company also benefits from licensing agreements with larger pharmaceutical firms, wherein it licenses its technology or product candid...
Ramm Pharma Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | Oct 2025 | Jan 2025 | Jan 2024 | Jan 2023 | Jan 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.36M | 4.34M | 5.07M | 3.90M | 4.12M |
| Gross Profit | 373.93K | 1.76M | 381.82K | 530.50K | -7.64K |
| EBITDA | -3.78M | -15.23M | -6.30M | -19.91M | -6.36M |
| Net Income | -8.91M | -16.50M | -7.72M | -20.96M | -7.11M |
Balance Sheet | |||||
| Total Assets | 9.27M | 16.75M | 32.30M | 39.31M | 59.71M |
| Cash, Cash Equivalents and Short-Term Investments | 803.88K | 814.04K | 5.12M | 9.77M | 17.16M |
| Total Debt | 80.39K | 188.31K | 405.14K | 683.70K | 32.16K |
| Total Liabilities | 3.57M | 3.11M | 2.84M | 3.72M | 3.32M |
| Stockholders Equity | 5.70M | 13.63M | 29.46M | 35.59M | 56.39M |
Cash Flow | |||||
| Free Cash Flow | -1.06M | -4.05M | -4.45M | -6.08M | -4.25M |
| Operating Cash Flow | -1.06M | -4.00M | -4.34M | -5.91M | -3.82M |
| Investing Cash Flow | 1.22M | -47.43K | 126.58K | -1.15M | -6.83M |
| Financing Cash Flow | -154.07K | -258.23K | -409.97K | -353.77K | -190.33K |
Ramm Pharma Technical Analysis
Negative
0.06
Price Trends
0.03
Negative
0.04
Negative
0.02
Negative
Market Momentum
>-0.01
Negative
30.24
Neutral
33.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:RAMM, the sentiment is Negative. The current price of 0.06 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.03, and above the 200-day MA of 0.02, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 30.24 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:RAMM.
Ramm Pharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$59.88M | -2.97 | -19.76% | ― | 26.91% | 81.01% | |
50 Neutral | C$9.23M | 5.19 | ― | ― | 15.64% | 58.47% | |
46 Neutral | C$1.79M | -0.20 | -82.37% | ― | -15.51% | -49.26% | |
46 Neutral | C$21.37M | -5.08 | -68.32% | ― | 2.41% | 74.61% | |
46 Neutral | C$29.92M | -6.72 | -71.80% | ― | -3.94% | -17.62% | |
45 Neutral | C$29.45M | -3.68 | -19.10% | ― | 18.06% | 34.58% |
* Healthcare Sector Average
TSE:RAMM
Ramm Pharma
0.02
>-0.01
-25.00%
TSE:ATLE
Willow Biosciences Inc
0.17
0.10
129.73%
TSE:LABS
MediPharm Labs
0.07
-0.03
-30.00%
TSE:PCLO
PharmaCielo
0.06
<0.01
9.09%
TSE:AVCN
Avicanna
0.17
-0.16
-48.48%
TSE:INNO
InnoCan Pharma
6.65
-5.70
-46.15%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.